Last Updated

10 Aug 2022

Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy (DMA)

Objectives

The primary objective is to determine if the efficacy of dihydroartemisinin-piperaquine (DP) with standard fixed artesunate-mefloquine regimen (MAS3) are superior to a longer regimen of artemether-lumefantrine (ALN+) in the treatment of uncomplicated malaria in pregnancy.

The study will also incorporate a dense pharmacokinetic study of mefloquine and artesunate (15 women in the MAS3 arm) and a population pharmacokinetic study for mefloquine, piperaquine and lumefantrine.

Principal Investigator
Study Design

This is a randomised, open label trial, comparing standard dose of dihydroartemisinin-piperaquine (DP) with standard fixed artesunate-mefloquine regimen (MAS3) and with a longer regimen of artemether-lumefantrine (ALN+) in the treatment of uncomplicated malaria in pregnant women. The sample size is 335 women in each arm which would be 1005 women in total. Pregnant patients in 2nd and 3rd trimester with acute uncomplicated malaria who meet eligibility criteria will be asked to participate in the study.

Thematic Categories

Date

2010 Feb - 2021 Jan

Funding Details

Project Site